Forbion European Acquisition Corp.

Status: Deal Closed
U=S+W/3 W=S@11.50
IPO Proceeds, $M $126.50M
IPO Date Dec 10, 2021
CEO Jasper Bos
Left Lead UBS
IPO Cash in Trust 102.5%
SPAC Tenor 18 + 3 + 3
IPO Sector Healthcare

Life sciences industry in Europe

IPO Geography Europe
Target Company enGene
Deal Announced May 17, 2023
Deal Size, $M $150.00M
Deal Sector Healthcare
Deal Geography Global
SEC Filings www.sec.gov
Approval Vote Oct 24, 2023
Amendment Vote TBD
Closing Date Oct 31, 2023
Formerly FRBN ENGN ENGNW

Sign up for Free Trial

No credit card required

Sign in for more on Forbion European Acquisition Corp.:

  • Structure and cap table
  • 7 directors & officers
  • 23 filings and events
  • 2 underwriters
  • 5 deal advisors
  • 6 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Jasper Bos 46 CEO and Director
Cyril Lesser 45 CFO and Director
Sander Slootweg 51 Director
Wouter Joustra 33 Director
Philip Astley-Sparke 50 Director
Hilde Steineger 55 Director
Ton Logtenberg 63 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
UBS Joint BR 8,525,000 units
Kempen & Co. Joint BR 2,475,000
11,000,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.50 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 23 filings.

Shareholders

Sign in to view shareholders 13F filing data.